{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:22:56Z","timestamp":1791559376465,"version":"4.3.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biomarkers that predict durable benefit from immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) in metastatic urothelial carcinoma (mUC) remain limited. Tertiary lymphoid structures (TLS), particularly mature TLS (mTLS) characterized by follicular dendritic cell networks and germinal centers, may reflect a highly compartmentalized antitumor immune niche.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 77-year-old man with bladder cancer and lung metastases experienced disease progression after two cycles of gemcitabine\/cisplatin. Pembrolizumab was initiated but discontinued after a single dose due to destructive thyroiditis; nevertheless, his lung metastases subsequently regressed. Because residual urothelial disease persisted in the bladder, enfortumab vedotin (EV) was initiated. A complete response (CR) was achieved after three cycles and maintained through 10 cycles, at which point treatment was stopped due to fatigue. The patient has remained recurrence-free for over 4 years since the initiation of pembrolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Immunohistochemistry of the pre-treatment transurethral resection of bladder tumor (TUR-Bt) specimen (CD3, CD4, CD8, CD20, CD21, BCL6) revealed numerous TLS adjacent to the tumor, many of which met the criteria for mTLS (CD21+ FDC networks and BCL6+ germinal center B cells). A HALO-based digital pathology spatial analysis demonstrated a highly enriched B- and T-cell microenvironment, with the vast majority of these lymphocytes tightly compartmentalized within the mTLS regions. In an exploratory cohort of six additional sequentially treated mUC cases evaluated using the same methodology, mTLS were not detected, even among cases exhibiting a generalized T-cell infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-existing mTLS identified in routine TUR specimens reflect a highly compartmentalized immune niche\u2014distinct from a simple \u201chot tumor\u201d phenotype\u2014that may help predict which patients are likely to achieve a durable benefit from sequential ICI and ADC therapy, potentially informing treatment selection and sequencing in mUC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1907498","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:36Z","timestamp":1788412896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Mature tertiary lymphoid structures in a metastatic urothelial carcinoma patient with an exceptional response to sequential immune checkpoint inhibitor and antibody-drug conjugate therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Kanta","family":"Hori","sequence":"first","affiliation":[{"name":"Department of Urology, Asahikawa Kosei General Hospital","place":["Hokkaido, Japan"]},{"name":"Departments of Pathology, Sapporo Medical University School of Medicine","place":["Hokkaido, Japan"]},{"name":"Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Sapporo Medical University School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Mizue","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Sapporo Medical University School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Asanuma","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Sapporo Medical University School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shijubou","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Sapporo Medical University School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Urology, Asahikawa Kosei General Hospital","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, Asahikawa Kosei General Hospital","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Furumido","sequence":"additional","affiliation":[{"name":"Department of Urology, Asahikawa Kosei General Hospital","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashige","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asahikawa Kosei General Hospital","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Hirohashi","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Sapporo Medical University School of Medicine","place":["Hokkaido, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: An intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385802","article-title":"Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000930","article-title":"Quantitative image analysis for tissue biomarker use: A white paper from the Digital Pathology Association","volume":"29","author":"Lara","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008875","article-title":"Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing","volume":"13","author":"Taube","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12764","article-title":"A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment","volume":"14","author":"Viratham Pulsawatdi","year":"2020","journal-title":"Mol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414884","article-title":"Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1915574","article-title":"Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer","volume":"10","author":"Zhou","year":"2021","journal-title":"OncoImmunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15976","article-title":"Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab","volume":"114","author":"Komura","year":"2023","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70978","article-title":"Tertiary lymphoid structures as independent predictors of favorable prognosis in muscle-invasive bladder cancer","volume":"14","author":"Teng","year":"2025","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410998","article-title":"Tertiary lymphoid structures are linked to enhanced antitumor immunity and better prognosis in muscle-invasive bladder cancer","volume":"12","author":"Lin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Combining antibody-drug conjugates with immune checkpoint inhibitors in solid tumors: rationale and clinical progress","volume":"33","author":"Nicol\u00f2","year":"2022","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091594","article-title":"Immune checkpoint inhibitors and antibody-drug conjugates in urothelial carcinoma: current landscape and future directions","volume":"17","author":"Yajima","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"450.e13","DOI":"10.1016\/j.urolonc.2024.06.010","article-title":"Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method","volume":"42","author":"Yilmaz","year":"2024","journal-title":"Urol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:37Z","timestamp":1788412897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1907498"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1907498","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1907498"}}